WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 20, 984-1002. Review Article ISSN 2277–7105

THE ROLE OF PROBIOTICS IN NEUROPSYCHIATRIC DISORDERS

Ainampudi Yedukondalu[1*], Konchada Tavin Raju[2], Meka Prasanth Kumar[3], Yarasani Larence[4], Jabeer Shaik[5], Muhammad shahid[6], Dr. Apada Reddy Gangadasu[7], Dr. B. Thangabalan[8]

[1*,2,3,4,5,6,7,8]SIMS College of Pharmacy, Guntur, Andhra Pradesh – 522001, India.

Article Received on
30 September 2023,

Revised on 21 Oct. 2023,
Accepted on 10 Nov. 2023

DOI: 10.20959/wjpr202320-30318

***Corresponding Author**
Ainampudi Yedukondalu
SIMS College of Pharmacy, Guntur, Andhra Pradesh – 522001, India.

ABSTRACT

Our review focused on the relationship between gut microbiota and neuropsychiatric diseases, highlighting the potential therapeutic effects of microbiota-targeted interventions. Recent studies, including a pilot randomized controlled trial on individuals with fibromyalgia, have demonstrated that administering a multispecies probiotic can improve attention, as shown by a significant decrease in errors of omission ($p < 0.01$). Additionally, probiotics enhanced bowel function compared to a placebo ($p < 0.001$). In patients with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS), treatments aimed at correcting gut dysbiosis have been associated with improvements in symptoms and sleep quality, along with reduced cognitive reactivity to sad mood ($p = .019$). Research in neurodegenerative disorders such as Parkinson's and Alzheimer's suggests that manipulating the gut microbiota through dietary changes, medicinal herbs, and colon cleansing can alleviate symptoms, with Parkinson's patients experiencing significant improvements in UPDRS III scores ($p < 0.033$). Furthermore, using Lactobacillus plantarum has been correlated with reduced depressive symptoms and better sleep quality, supported by improved sleep measures and cortical excitation ($p < 0.05$). These findings indicate a significant role of the gut-brain axis in neuropsychiatric health and suggest that microbiota-targeted therapies, including diet modifications, probiotics, and fecal microbiota transplantation, may effectively manage these conditions. However, further high-quality research is essential for translating these promising results into clinical practice.

KEYWORDS: Microbiota, Probiotic, Neuropsychiatric, Psychiatric disorders, multi-probiotic strains.

INTRODUCTION

Microbiota refers to the assemblage of microorganisms, encompassing bacteria, fungi, viruses, and other microbial entities, that inhabit and colonize the human body. The human microbiota is comprised of a vast number of bacteria, estimated to be in the trillions, which reside in many regions of the body, including the skin, oral cavity, respiratory system, and particularly the gastrointestinal tract. Microorganisms are of paramount importance in preserving the general well-being and operational efficiency of the human body. These microbes are present in several anatomical regions, including the gastrointestinal tract, mouth and nasal mucosa, vaginal canal, and integumentary system. The organisms establish an intricate ecological system characterized by interactions with the host organism and the surrounding environment. External influences, including nutrition, antibiotics, and medicine, have the potential to exert an impact on the composition and diversity of microbiota. Dysbiosis, characterized by alterations in the microbiota composition, has been linked to the onset and persistence of inflammatory conditions such as chronic inflammatory bowel disease. The microbiota is known to have a significant impact on both physiological and pathological processes. It is widely acknowledged as a vital organ that performs many activities, such as the metabolism of food and the education of the immune system. The gut microbiota can impact the brain through several pathways, such as the vagus nerve, the hypothalamus-pituitary-adrenal axis, the metabolism of neuroactive chemicals, and the control of host inflammation. The microbiome can also exert an influence on hippocampus functioning via dopaminergic and noradrenergic processes, which have been linked to psychopathological conditions such as addiction and schizophrenia. The precise impacts and underlying processes by which bacteria influence brain function are currently under investigation.

Importance of Microbiota

The microbiota is known to have a significant impact on the maturation and development of the immune system, central nervous system (CNS), and gastrointestinal tract (GIT) system. The gut microbiota plays a crucial role in fundamental metabolic processes. The occurrence and advancement of neurological illnesses have been linked to dysbiosis, an imbalance in the gut microorganisms. The gut microbiota has a significant influence on the composition of microbial metabolites inside the gastrointestinal tract, which in turn can have an impact on the physiological and neurochemical functioning of enteric neurons. The gut microbiota plays a crucial role in preserving intestinal well-being and inhibiting the proliferation of

pathobionts, which have the potential to induce illnesses in the host organism. Many elements, including host genetics, environmental conditions, individual lifestyle choices, dietary patterns, and the utilization of medications, influence the gut microbiota. The microbiota exerts a substantial influence on both the well-being and pathogenesis of humans. It plays a role in the initiation, preparation, and execution of the host immune response. Short-chain fatty acids (SCFAs) generated from the microbiota possess immunomodulatory properties and play a crucial role in maintaining homeostasis. The microbiota has been associated with intricate illnesses, such as cancer. The components of intratumoral microbiota strongly correlate with cancer genesis, progression, and treatment effectiveness. The manipulation of microbiota composition can potentially impact the efficacy of tumor treatment and the development of therapeutic resistance. The microbiota can modulate the physiological characteristics of cancer cells and influence the immune response using many signaling pathways. Additionally, these compounds are involved in the development of cardiovascular disease since they can generate metabolites that are toxic to blood vessels and can impact cellular signaling pathways. Alterations in the microbial population have the potential to give rise to many illnesses, including cardiovascular, neurological, and gastric ailments.

GUT-BRAIN AXIS

The gut-brain axis denotes the reciprocal communication network between the gastrointestinal tract, often the gut and the brain. The phenomenon encompasses intricate interplays among the central neurological system (CNS), the enteric nervous system (ENS), the gut microbiota, and the endocrine and immunological systems. The inception of the gut-brain axis may be traced back to the 1980s when scientific investigations on hormone signaling within the gastrointestinal system and its interrelation with the brain were conducted. Over time, the notion has broadened to encompass the involvement of gut bacteria in this axis. The gut-brain axis plays a crucial role in the regulation of several physiological processes surrounding digestion, metabolism, immunological function, as well as mood and behavior. The pathogenesis of mental health diseases, such as depression, has been associated with changes in the makeup of the gut microbiota and its metabolites. Comprehending the gut-brain axis is of utmost importance in advancing novel therapy strategies for mental health disorders. The gut-brain axis pertains to the reciprocal exchange of information between the gastrointestinal (GI) system and the central nervous system (CNS). The gastrointestinal (GI) tract and the central nervous system (CNS) engage in reciprocal interactions through various

processes. The enteric nervous system, an inherent component of the gastrointestinal tract, governs gastrointestinal activities by interacting with the immune system and microbiota. Extrinsic signals influence gastrointestinal functioning and transmit sensory information to the central nervous system (CNS). The transmission of visceral impulses occurs through the spinal cord and brainstem, where they are subsequently integrated into the corticolimbic brain circuitry. Descending signals originating from the brainstem influence the gastrointestinal system by modulating vagal and spinal signaling pathways. The impression of visceral discomfort can be heightened by peripheral or central sensitization, which can be triggered by inflammation or stress. Several neurophysiological approaches have been devised to investigate the gut-brain axis, such as the recording of cerebral evoked potentials, functional brain imaging, and the assessment of vagal tone. The gut-brain axis is subject to the effect of the gut microbiota, which establishes communication with the brain through the gut-brain axis and can potentially affect brain functioning and disorders. The comprehension of the gut-brain axis has undergone development, with a historical acknowledgment of the correlation between the gastrointestinal system and emotional states. The potential influence of the gut microbiota on emotions, motivation, mood, and higher cognitive abilities has been suggested. Probiotics, prebiotics, and postbiotics have demonstrated promising effects in mitigating depressive symptoms in individuals diagnosed with major depressive disorder. The gut microbiome of individuals diagnosed with Alzheimer's disease (AD) has been observed to have a reduced prevalence of anti-inflammatory microorganisms and an elevated prevalence of pro-inflammatory microorganisms. The potential impact of the gut microbiota on the central nervous system in individuals with Alzheimer's disease (AD) may give rise to neuroinflammation and a loss of cognitive function. The gut-brain-microbiota axis plays a significant role in the pathogenesis of functional gastrointestinal diseases, including irritable bowel syndrome and inflammatory bowel disease. The gut microbiota influences the development and functionality of the brain and enteric nervous system.

ROLE OF PROBIOTICS IN NEUROLOGICAL DISORDERS

Probiotics have demonstrated potential in the treatment of neurological illnesses, especially neurodevelopmental conditions like autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). The gut microbiota facilitates bidirectional communication between the gastrointestinal tract and the central nervous system. Probiotics have been seen to influence this connection by producing neurotransmitters and microbial metabolites. Research findings have indicated that specific strains of probiotics, including Lactobacillus

and Bifidobacterium, have demonstrated notable efficacy in alleviating the symptoms associated with Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) among pediatric populations. Probiotics have also been examined for their possible therapeutic effects in many neurological and psychiatric illnesses, such as anxiety, major depressive disorder, bipolar disorder, schizophrenia, and cognitive impairments. The methods by which probiotics exert their effects encompass neurological, hormonal, and immunological pathways. Nevertheless, more investigation is required to validate the enduring safety and efficacy of probiotics in the management of neurological diseases.

Probiotics have demonstrated potential in the prevention and management of Alzheimer's disease (AD) by providing neuroprotective advantages, mitigation of cognitive impairments, and regulation of dysbiosis in the gut microbiota. The intricate microorganisms residing in the gastrointestinal tract of humans, commonly referred to as the gut microbiome, exhibit a strong correlation with Alzheimer's disease (AD). The gut microbiota influences brain health by modulating several physiological systems, encompassing the metabolic, immunological, neurological, and endocrine systems. Nevertheless, in cases of gut dysbiosis and impairment of gut barriers, pathobionts have the potential to disturb the equilibrium of these systems, resulting in the decline of brain functioning and the onset of Alzheimer's disease (AD). Various therapeutic techniques, including the utilization of probiotics, have been the subject of discussion as prospective therapy modalities for Alzheimer's disease (AD). These approaches aim to manipulate the gut microbiome to counteract degenerative changes occurring within these systems. Additional comprehensive clinical trials are required to investigate the possible efficacy of probiotics in mitigating the effects of Alzheimer's disease (AD). Within the realm of fibromyalgia syndrome (FMS), empirical investigations have indicated that individuals afflicted with FMS exhibit a modified composition of intestinal microbiota, characterized by reduced quantities of advantageous bacteria such as Bifidobacterium, and elevated quantities of harmful bacteria such as Enterococcus spp. The gut microbiota is pivotal in various physiological processes, encompassing energy metabolism and psychological welfare. The gut-brain axis facilitates bidirectional communication between the brain and the gastrointestinal system through neuronal, endocrine, and immunological pathways. The potential therapeutic use of modulating the gut microbiota, such as by the use of probiotics, has been proposed for the treatment of fibromyalgia syndrome (FMS) and other associated disorders. The potential therapeutic effects of probiotics in mitigating cognitive impairment and depressive disorders have been

suggested, with the postulated mechanism of action being the modulation of the gut-brain axis in both human patients and animal models. Applying probiotics in managing gut microbiome dysbiosis has exhibited encouraging benefits in enhancing therapeutic outcomes in neurological illnesses. The synthesis of metabolites by probiotics, namely Bifidobacterium and lactic acid-producing bacteria, has been observed to have significant implications for the modulation of neurological function. Several human studies have demonstrated the beneficial effects of probiotic strains, including Lactobacillus acidophilus LA5, Bifidobacterium lactis BB12, and Bifidobacterium longum NCC3001, on anxiety, depression, and stress reactions. Probiotics have been seen to influence the makeup of the gut microbiota and facilitate the release of serotonin, potentially bearing significance for neurological illnesses. Further investigation is required to comprehensively comprehend the processes and precise impacts of probiotics on neurological illnesses. Nonetheless, these findings indicate a prospective therapeutic function for probiotics in regulating the gut-brain axis and mitigating neurological symptoms. The role of the gut microbiota has been suggested in the etiology of neurological conditions, encompassing mental diseases such as depression, bipolar disorder, schizophrenia, and anxiety.

Observations have been made on alterations in the makeup of the gut microbiota in mental diseases, characterized by a decrease in bacteria that produce anti-inflammatory butyrate and an increase in bacteria that promote inflammation. The gut-brain axis, indicated by reciprocal communication between the gut microbiota and the brain, is a pivotal factor in the emergence and advancement of neurological diseases. The gut microbiota can generate metabolites that impact brain function and behavior, such as neurotransmitters like GABA and serotonin. The effect of diet in modifying the gut microbiota and its influence on neurological illnesses is of considerable importance. A dietary pattern characterized by a diverse range of fiber sources, phytochemicals, and beneficial living bacteria can foster a healthy gut microbiota and perhaps enhance the management of brain illnesses.

The potential therapeutic effects of probiotics, namely Helvetica, have been demonstrated in persistently stressed rats by restoring hippocampus serotonin levels, suggesting a positive impact on memory. Research conducted on rodents has provided evidence indicating that the microbiota has the potential to impact the shape and plasticity of the hippocampus, as well as the behaviors associated with it. These findings underscore the significance of the gut microbiota in regulating learning and memory processes that rely on the hippocampus. The

investigation of gut microbiota's alpha and beta diversity in psychiatric diseases has been a subject of study. Among the diversity indices used, the Shannon and Simpson indexes have received significant attention. Extensive study has been conducted on psychiatric diseases at the phylum level, explicitly focusing on Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia. At the taxonomic rank of genus Prevotella, Coprococcus, Parabacteroides, Phascolarctobacterium, Escherichia Shigella, Alistipes, Sutteralla, Veillonella, Odoribacter, Faecalibacterium, Bacteroides, Bifidobacterium, Dialister, and Blautia have been found to have associations with psychiatric problems. The precise processes that underlie the involvement of gut microbiota in mental diseases remain unclear. However, there is promise for therapeutic interventions by regulating gut microbiota through dietary modifications, probiotic supplementation, or fecal microbial transplants (FMT).

Literature Review

A systematic review and meta-analysis of Cardona et al. (2021). They investigated probiotics' function in cognitive processes among patients diagnosed with fibromyalgia syndrome (FMS). It demonstrated probiotics' acknowledging impact on cognition in human and animal subjects, with attention and memory enhancements observed among Alzheimer's patients, healthy elderly individuals, and those with depression. The meta-analysis concluded that using a solitary probiotic strain was more efficacious than a combination. A lengthier treatment duration of 12 weeks was more effective than eight weeks. Particularly, trials have shown that administering particular probiotic strains, like Lactobacillus plantarum 299v and Lactobacillus plantarum DR7, has improved attention and memory among patients with major depression and healthy adults, respectively. However, this current study was subject to certain limitations, such as its small sample size and the absence of information on participants' nutritional habits and gut microbiota. To obtain more definitive answers regarding probiotics' effectiveness in FMS, future studies should be designed with larger sample sizes and consider these limitations.[1]

In this academic discourse, we will engage in a systematic review of the scholarly work conducted by Yaning Zang et al. (2023). This article conducted an evidence mapping to examine the association between gut microbiota and neurological and psychiatric disorders, including a range of conditions such as Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder, major depressive disorder (MDD), and schizophrenia. A total of 42 papers were used in the analysis, predominantly consisting of observational studies. The methodological quality of

this research was assessed utilizing the AMSTAR-2 tool. The data analysis demonstrated a range of levels of support for the connections between gut microbiota and neurological disorders. The illnesses listed before were shown to be associated with certain bacteria, including Coprococcus and Parabacteroides. Furthermore, the paper explored the potential application of probiotics, dietary modifications, and fecal microbial transplants as prospective therapeutic approaches for neurological and psychiatric conditions. The research was carried out via a four-phase process, encompassing search strategy and selection, assessment of study quality, extraction of data, and synthesis and analysis of data.[2]

The study conducted by Azliza Ibrahim et al. is a randomized controlled trial. The present research study, titled "Examining the Effectiveness of Multi-Strain Probiotics (Hexbio) Containing MCP BCMC Strains in Alleviating Constipation and Enhancing Gut Motility in Individuals with Parkinson's Disease," sought to explore the effectiveness of a probiotic formulation containing multiple strains in ameliorating symptoms of constipation and promoting healthy gut movement in individuals diagnosed with Parkinson's disease and experiencing constipation. The research was an intervention trial lasting eight weeks, employing a double-masked, randomized, and placebo-controlled design. The study included a total of 55 individuals diagnosed with idiopathic Parkinson's disease. The study evaluated the primary outcomes by examining changes in constipation symptoms as measured by the Garrigues Questionnaire and the frequency of bowel movements. The additional outcomes assessed in this study were gastrointestinal transit time, quality of life, and motor and non-motor complaints. The findings of the study indicated that the group administered probiotics exhibited a statistically significant increase in the average number of weekly bowel movements in comparison to the group aided with a placebo. Therefore, the study concluded that the administration of a multi-strain probiotic resulted in an improvement of constipation symptoms and enhanced gut motility in individuals diagnosed with Parkinson's disease and experiencing constipation.[3]

The study's authors, Amy Wallis et al., focus on Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This complex neuroimmunological condition is distinguished by mental and physical weariness following exercise, disproportionate to the amount of effort. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) impacts several physiological systems, such as the central neurological, immunological, gastrointestinal, energy metabolism, cardiovascular, and respiratory systems, leading to a wide range of clinical manifestations. It is frequently seen that individuals diagnosed with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) often encounter disruptions in their gastrointestinal functioning, accompanied by the presence of irritable

bowel syndrome (IBS) as a comorbidity. It has been estimated that about 80-90% of these patients consistently show gastrointestinal symptoms. Previous research has shown disparities in the gut microbiota, also known as the microbiome, among individuals diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). These disparities are distinct from those observed in individuals without ME/CFS and have been associated with both inflammation and the manifestation of symptoms. The potential involvement of the enteric microbiota in the gut-brain axis suggests a possible role in developing neurological symptoms observed in individuals with ME/CFS. Preliminary evidence suggests that directing therapeutic interventions towards gut dysbiosis, particularly the excessive proliferation of Streptococcus species, can improve the clinical results of individuals with ME/CFS. Using antibiotic, probiotic, and fecal transplant therapies has shown preliminary evidence supporting the role of microbiota-gut-brain interactions in the context of ME/CFS. Additional research is required to have a comprehensive understanding of the mechanisms underlying microbial-host communication and to investigate alternate approaches for tailored therapeutic interventions.[4]

The study's authors, Chong-Su Kim et al., conducted a multicenter trial employing randomization, double-masking, and placebo control to examine the impact of probiotics on cognitive performance and mood in older persons living in the community. The core measures assessed in the study encompassed cognitive performance and mood evaluations. In contrast, the secondary measures contained the makeup of gut microbiota and indicators of neuronal biochemistry, including brain-derived neurotrophic factor (BDNF). The study utilized the Korean adaptation of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K) as a tool for evaluating cognitive performance across many domains. The research findings revealed that probiotics exerted comprehensive effects on the gut-brain axis in older persons who were in good health. These effects encompassed the enhancement of cognitive and mental well-being, as well as alterations in the makeup of gut microbial communities. The relative quantity of gut bacteria that induce inflammation was shown to be dramatically decreased in the group receiving probiotics. Furthermore, the probiotics group exhibited more pronounced improvements in mental flexibility and stress ratings than the placebo group. The administration of probiotics resulted in a significant rise in serum brain-derived neurotrophic factor (BDNF) levels. Additionally, the alterations in gut microbial composition induced by probiotics exhibited a negative association with serum BDNF levels. The results of this study provide evidence that probiotics had health-enhancing characteristics when incorporated into the dietary regimen of elderly individuals.[5]

In this literature review, Peterson et al. (year) examine the dysfunction of the microbiota-gut-brain axis in neurodegenerative illnesses and explore the possible therapeutic manipulation of this axis through prebiotics, medicinal herbs, probiotics, and synbiotics. Animal models have shown evidence that the administration of bacopa has the potential to protect cholinergic neurons and improve memory impairments associated with Alzheimer's Disease (AD). The gut microbiota plays a crucial role in maintaining health and contributing to the development of diseases. It consists of about 1,000 species and 50 phyla that inhabit the human gastrointestinal tract. The research emphasizes the need for more well-designed, extensive, long-term clinical trials to acquire a more profound understanding of the microbiota-gut-brain axis and its potential therapeutic applications in both general health and neurological disorders. The author declares no possible conflicts of interest and admits to receiving financial assistance from the Chopra Foundation. Neurodegenerative disorders, such as Parkinson's illness (PD) and Alzheimer's Disease (AD), pose a significant worldwide health challenge, necessitating the identification of biomarkers for early illness detection.[6]

In their comprehensive study, Shokufeh et al. examine The gut microbiome, which is known to have a significant impact on the development and maturity of the immune system, gastrointestinal tract, and central nervous system, as well as being responsible for essential metabolic pathways. Dysbiosis, an imbalance in the gut microbiota, has been associated with the initiation and advancement of neurological illnesses. Several variables, including genetic predisposition, environmental elements, lifestyle choices, dietary patterns, and pharmaceutical consumption, can influence this dysbiosis. Various neurological illnesses, such as autism spectrum disorders (ASD), Parkinson's disease (PD), schizophrenia, multiple sclerosis (MS), Alzheimer's disease (AD), epilepsy, and stroke, have been linked to alterations in the gut microbiota. Microbial-based interventions, including probiotics, prebiotics, postbiotics, synbiotics, and fecal microbiota transplantation (FMT), have been recognized as prospective therapeutic modalities for neurological illnesses. However, further clinical studies and research are required to establish the efficacy of these interventions and find the most appropriate doses. The influence of the gut microbiota on brain development, mood, and behavior is well-documented. Consequently, the strategic manipulation of the gut microbiota through dietary treatments has excellent potential for the prevention and treatment of mental and behavioral disorders. Microbial therapies, such as fecal microbiota transplantation (FMT), have demonstrated promising potential in mitigating symptoms and exerting immunoregulatory effects in neurological illnesses such as Alzheimer's disease (AD) and multiple sclerosis (MS). Further research is necessary to evaluate the role of gut microbiota in the course of diseases and ascertain the most effective therapies.[7]

Tobias Hegelmaier and colleagues conducted the study. This study explores the impact of the gut microbiota on Parkinson's disease. It examines the possible benefits of dietary intervention and stool cleansing in alleviating motor symptoms among individuals with PD. The present study employed a case-control approach to investigate the gut microbiome in a cohort of 54 individuals diagnosed with Parkinson's disease (PD) and 32 healthy controls. The findings of this study provide further support for previously documented alterations in the microbiome related to PD. The study implemented a precise intervention consisting of a controlled and balanced ovo-lacto vegetarian diet for 14 days. This intervention resulted in significant improvements in the UPDRS III motor score and a decrease in the levodopa-equivalent daily dosage throughout a one-year follow-up period. Furthermore, the implementation of further therapy, including the administration of fecal enemas daily for eight days, resulted in a subsequent reduction in the prevalence of Clostridiaceae within the gastrointestinal microbiota. The research suggests that implementing dietary modification and colon cleaning might potentially serve as non-pharmacological therapy approaches for those with Parkinson's disease.[8]

The authors of the study are Yu-Ting Ho and colleagues. The objective of this study was to assess the potential of Lactobacillus plantarum PS128 in reducing the intensity of anxiety and depression symptoms, regulating the functioning of the autonomic nervous system, and improving the quality of sleep. The research encompassed a cohort of 40 individuals who self-identified as experiencing insomnia. These participants were then randomly allocated to two groups: the PS128 group and the placebo group. Over 30 days, the participants were given two capsules, either containing PS128 or a placebo, following their evening meal. The study included subjective measures such as depressed symptoms, anxiety, and sleep questionnaires, together with micro polysomnography recordings, to assess the impact of the therapy. These assessments were conducted at the beginning of the study and on the 15th and 30th days. The group identified as PS128 had noteworthy reductions in scores on the Beck Depression Inventory-II, levels of exhaustion, brainwave activity, and instances of waking during the deep sleep period compared to the control group. The findings suggest that regular intake of PS128 may lead to a reduction in depressed symptoms, weariness, and cerebral excitation, as well as an improvement in sleep quality, namely during the deep sleep phase—the Brain Research Center at National Yang-Ming Chiao Tung University.[9]

In this comprehensive review, Kuijer et al. (year) elucidate the considerable research conducted on the microbiota-gut-brain axis, particularly about stress-related psychopathology, namely depression and

anxiety. Research conducted on mice has shown evidence that the gut microbiota has a substantial role in influencing learning and memory processes dependent on the hippocampus. Nevertheless, there is a scarcity of understanding of the pathways between gut microbiota and the hippocampus in both healthy and diseased states, as well as the applicability of these findings to human subjects. To assess the impact of gut microbiota on hippocampal-dependent functioning, this review suggests a methodology that examines biomarkers derived from four key pathways: the vagus nerve, hypothalamus-pituitary-adrenal axis, metabolism of neuroactive substances, and modulation of host inflammation. This paper further emphasizes the difficulties encountered in microbiota-hippocampus research, including individual variability, inadequate understanding of the intricate interplay between microbiota composition and hippocampal functioning, and the little impact shown in therapies based on microbiota. Although there is evidence from rat research that supports the involvement of gut microbiota in regulating learning and memory processes in the hippocampus, it is essential to note that these discoveries are still in the early stages. The underlying mechanisms are not yet fully understood. The investigation of the relationship between the microbiota and hippocampal-dependent processing in humans is now in its early stages. Nevertheless, the administration of prebiotic supplements has exhibited improvements in cognitive functions associated with the hippocampus. The involvement of gut microbiota and hippocampus functioning has been implicated in clinical diseases such as Alzheimer's disease and irritable bowel syndrome.[10]

Laura Steenbergen and her colleagues conducted the study. The present investigation investigates the effects of multispecies probiotics on cognitive response to sad mood among adults who do not exhibit symptoms of depression. Throughout the 4-week intervention, the participants were administered a probiotic food-supplement intervention, including multispecies probiotics. In contrast, the control group received a placebo that lacked active ingredients for the same duration. The study's results suggest that participants who received the probiotics intervention saw a notable decrease in their cognitive reactivity to sad moods. This decrease was mainly related to a reduction in rumination and angry thoughts. Prior studies have established that ruminative thoughts have the potential to elicit periods of depression. In contrast, the activation of violent thoughts has been associated with the occurrence of suicidal ideation and attempts. Therefore, the findings of this study suggest that the use of probiotics supplements may be a viable approach for the prevention of depression, and so merits more research. The study presents substantial evidence supporting the notion that probiotics can effectively reduce negative thoughts connected with feelings of sadness and impact cognitive processes linked to the susceptibility to mood disorders.[11]

The authors of the study are Tracey L K Bear and colleagues. This article explores the rising body of data that suggests a correlation between a poor food pattern and an increased susceptibility to the development of depression or anxiety disorders. On the other hand, a well-designed dietary plan has the potential to alleviate this issue. The correlation between dietary patterns and emotional well-being is complex and influenced by several factors that can sometimes lead to inconsistent findings across different research investigations. The gut microbiota and the brain are intricately linked by a two-way connection known as the microbiome-gut-brain axis, which governs brain function and behavior. The correlation between diet and mood is likely interconnected with the composition of the gut microbiota, which might potentially explain the inconsistent findings shown in research investigating the association between food and depression. A meta-analysis of prospective studies revealed a significant association between adherence to a high-quality diet, higher consumption of fish and vegetables, and a reduced risk of developing depression. On the contrary, there was no observed association between a diet of poor nutritional quality and an elevated susceptibility to depression. Randomized controlled trials (RCTs) have demonstrated considerable heterogeneity in study design and treatments. However, therapies that have consistently shown efficacy in alleviating depression symptoms often involve the cultivation of vegetables. In many instances, nutrition studies lack sufficient oversight or consideration of psychological factors, hence neglecting the potential influence of individual psychological features on the magnitude and significance of the association between food and depression.[12]

The authors of the study, Briela Ribeiro et al., This article explores the importance of nutrition in modulating the interaction between the microbiota-gut-brain axis and its possible impact on brain health and behavior. While the incorporation of the microbiome into clinical nutrition views on brain health remains restricted, recent research suggests that dietary interventions aimed at modulating the microbiota have the potential to improve brain illnesses. Nevertheless, research on the impacts of the diet-microbiome-behavior nexus in humans encounters challenges, including individual variations within the microbiome and constraints in accurately evaluating food consumption and compliance. The current state of microbiome studies reveals a lack of established methods for dietary evaluation or therapies. However, there is a noticeable increase in interest in translating diet-microbiome-brain discoveries into clinical research. The gut microbiota, short-chain fatty acids (SCFAs), and dietary variables, including dietary fiber and phytochemicals, play a pivotal role in the microbiota-gut-brain axis and can be modulated by dietary interventions. Nutritional therapies aimed at modulating the gut microbiota have potential in the prevention and management of mental health problems. However, it is crucial to acknowledge and rectify methodological constraints while also gathering robust data on the interplay between the microbiome, brain function, and behavior. Several recent studies have

demonstrated the efficacy of dietary therapies in mitigating symptoms of depression and other mental diseases.[13]

The authors of the study, Kazunori Suda et al., investigate the influence of the gut microbiota on the cognitive functions and psychological state of the host through the gut-brain axis, as well as its interaction with mental health disorders, particularly major depressive disorder (MDD). The findings from animal trials suggest that the reduction of gut microbiota leads to behavioral modifications and pathological abnormalities, such as abnormal stress response and compromised adult neurogenesis. The presence of gut dysbiosis leads to a decrease in brain-derived neurotrophic factor (BDNF) levels, potentially causing adverse effects on the development of neurons and the plasticity of synapses. Additionally, heightened intestinal permeability elicits systemic inflammation and neuroinflammation inside the central nervous system. The article also explores the potential therapeutic benefits of probiotics, namely bacteria that produce butyrate, in modulating the microbiota-gut-brain axis and alleviating symptoms of depression. This study investigates the possible use of probiotics, namely lactobacilli, bifidobacteria, and butyrate-producing bacteria, as a therapeutic approach to alter the pathophysiology of depression.[14]

The study's authors, Lijia Chang et al., provide a thorough historical analysis and present potential future directions for the brain-gut-microbiota axis in depression. This statement highlights the significant impact of the brain-gut-microbiota axis on the development and manifestation of mental health problems, specifically depression. The paper emphasizes the interconnected and reciprocal relationship between the brain-gut-microbiota axis in the context of depression. Furthermore, this highlights the elusive characteristics of the specific processes that govern the involvement of the brain-gut-microbiota axis in the development of depression. Additionally, the study highlights the participation of different networks, including the brain signal network, immunological signal network, and chemical signal network, in the pathophysiology of depression. Additionally, the research highlights an increase in the identification and analysis of changes in gut microbiota and associated metabolic disruptions in individuals diagnosed with depression. Further, this study underscores the significance of dietary factors in depression, emphasizing the potential benefits of implementing healthy nutritional treatments for the prevention and mitigation of depressive symptoms.[15]

RESULTS

Recent research has revealed encouraging findings in assessing the relationship between gut microbiota and neuropsychiatric diseases. The findings of a pilot randomized controlled trial conducted on individuals with fibromyalgia demonstrated that the administration of a multispecies probiotic had a

positive impact on attention. This was evidenced by a statistically significant decrease in errors of omission observed during attention tests ($p < 0.01$). In a distinct investigation centered on bowel function, those administered probiotics had considerably superior outcomes than those who received a placebo ($p < 0.001$).

Additional investigation into the condition known as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) has revealed that therapies targeting the correction of gut dysbiosis through the use of antibiotics and probiotics have resulted in notable enhancements in symptomatology and sleep quality. Using probiotics was also linked with decreased cognitive reactivity towards sad moods. This association was seen to be significant over time ($p = .019$), indicating a possible impact on the regulation of mood.

Studies on neurodegenerative disorders such as Parkinson's and Alzheimer's have demonstrated a correlation between the manipulation of the gut microbiota and the amelioration of symptoms. This manipulation encompasses several approaches, including medicinal herbs, dietary modifications, and colon-cleansing techniques. Significantly, individuals diagnosed with Parkinson's who underwent microbiota-targeted therapy had noteworthy improvements in UPDRS III scores ($p < 0.033$).

Furthermore, there exists a correlation between the administration of Lactobacillus plantarum and a reduction in depressed symptoms as well as an improvement in sleep quality. This correlation is supported by substantial improvements seen in measures of sleep and cortical excitation, with a p-value less than 0.05.

The studies above combined underscore the significance of the gut-brain axis in the context of neuropsychiatric health and illness. Additionally, the authors emphasize the potential efficacy of microbiota-targeted therapies, such as modifications to dietary patterns, administration of probiotics, and the transplantation of fecal microbiota, in managing these illnesses. Nevertheless, to translate these encouraging findings into practical applications, it is imperative to do more research of superior quality.

DISCUSSION

The latest findings from many research investigating the impact of the gut microbiota on neuropsychiatric disorders provide valuable insights into prospective treatment strategies for effectively treating these intricate illnesses. The present discourse incorporates the results above and examines their potential ramifications for future scholarly investigations and practical applications in clinical practice.

The findings of this study indicate that the administration of a multispecies probiotic to individuals with fibromyalgia has a discernible effect on cognitive function. Notably, improvements were observed in attention, but memory did not exhibit significant enhancement. These results show that particular strains of probiotics may possess cognitive advantages that are distinct. Further work is necessary to understand the precise mechanism by which these probiotics enhance attentional activities. However, it is plausible that this effect is mediated by modifying gut-brain communication pathways that impact neurocognitive circuits.

The observed improvement in bowel function with probiotics is consistent with the current understanding of the gut microbiota's influence on gut motility and its possible connection to overall health, including neuropsychiatric effects. Nevertheless, the correlation between enhanced gastrointestinal activity and neuropsychiatric manifestations has yet to be understood entirely.

The observed improvement in sleep quality and cognitive symptoms among patients diagnosed with ME/CFS suggests that using antibiotics and probiotics to treat gut dysbiosis has demonstrated efficacy. This observation may indicate the potential influence of the microbiome on inflammatory pathways that are believed to have a role in the development of ME/CFS.

The potential therapeutic use of probiotics in mitigating cognitive sensitivity to sad mood suggests a promising option for addressing mood disorders. The precise impact of the microbiota on rumination and aggressive ideation has the potential to inform tailored therapies in the context of depression.

The potential therapeutic benefits of modulating the gut microbiota in neurodegenerative disorders, such as Parkinson's and Alzheimer's, suggest a promising avenue for controlling these ailments. The potential of nutritional and microbiological therapies is emphasized by the notable modifications observed in established indices of disease severity, such as the UPDRS III.

The study on Lactobacillus plantarum is of particular significance as it provides empirical support for its impact on symptoms of depression and the quality of sleep. This observation suggests a potential trend toward the utilization of non-pharmacological interventions for the management of depression and related disorders.

However, it is essential to acknowledge the variability in the methodological rigor seen among different investigations. The stated advancements of notable magnitude necessitate careful consideration of potential bias and the imperative for rigorous, randomized controlled trials. The presence of variation in probiotic strains, doses, treatment durations, and outcome measures among various trials poses a

significant challenge in formulating overarching findings. Implementing standardization in future research endeavors may enhance the process of translating these first findings into therapeutic recommendations.

CONCLUSION

Recent research has provided mounting evidence indicating a substantial involvement of the gut microbiota in the development and manifestation of neuropsychiatric diseases. The therapeutic potential of targeting the gut-brain axis is underscored by the observed improvements in attention among fibromyalgia patients and enhanced bowel function attributed to the administration of probiotics. Additionally, specific strains such as Lactobacillus plantarum have been found to alleviate depressive symptoms and improve sleep quality, further emphasizing the potential benefits of this approach. Furthermore, the documented alleviation of symptoms in neurodegenerative illnesses with treatments that target the microbiota, such as dietary adjustments, presents an intriguing and potentially compelling approach to therapy. Notwithstanding the enthusiasm evoked by these findings, the heterogeneity in research methodologies and the varying levels of evidence quality call for a prudent approach to their interpretation. To create definitive therapeutic standards, future research endeavors must prioritize methodological rigor and consistency. However, the present results provide a foundation for incorporating interventions that modify the microbiota into comprehensive therapeutic approaches for neuropsychiatric disorders. This supports the need to transition towards personalized medicine and gain a more profound comprehension of the microbiome's impact on mental well-being.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

ACKNOWLEDGMENTS

The authors acknowledge, “This review received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.”

REFERENCES

1. Cardona, D. Roman, P. Canada, F.; Sánchez-Labraca, N. The Effect of Multiprobiotics on Memory and Attention in Fibromyalgia: A Pilot Randomized Controlled Trial. Int. J. Environ. Res. Public Health, 2021; 18: 3543. https://doi.org/10.3390/ijerph18073543.
2. Azliza Ibrahim, Raja Affendi Raja Ali, Mohd Rizal Abdul Manaf, Norfazilah Ahmad, Farah Waheeda Tajurruddin, Wong Zhi Qin, Siti Hajar Md Desa, Norlinah Mohamed Ibrahim, Multi-strain

probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease, https://doi.org/10.1371/journal.pone.0244680

3. Chong-Su Kim, Lina Cha, Minju Sim, Sungwoong Jung, Woo Young Chun, Hyun Wook Baik, Dong-Mi Shin, Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community PMCID: PMC7861012DOI: 10.1093/gerona/glaa090, DOI - PMC - PubMed.
4. Christine Tara Peterson Dysfunction of the Microbiota-Gut-Brain Axis in Neurodegenerative Disease: The Promise of Therapeutic Modulation With Prebiotics, Medicinal Herbs, Probiotics, and Synbiotics, PMID: 33092396PMCID: PMC7586271DOI:10.1177/2515690X20957225, DOI - PMC - PubMed.
5. Shokufeh Ghasemian Sorboni, a Hanieh Shakeri Moghaddam, b Reza Jafarzadeh-Esfehani,c,d Saman Soleimanpour e,f,g A Comprehensive Review on the Role of the Gut Microbiome PMID: 34985325PMCID: PMC8729913DOI: 10.1128/CMR.00338-20 DOI - PMC – PubMed,
6. Tobias Hegelmaier, Marco Lebbing, Alexander DuschaLaura Tomaske, Lars Tönges, Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing, PMID: 32041265 PMCID: PMC7072275, DOI: 10.3390/cells9020376 DOI - PMC - PubMed.
7. Yu-Ting Ho, Ying-Chieh Tsai, ORCID, Terry B. J. Kuo and Cheryl C. H. Yang, Effects of Lactobacillus plantarum PS128 on Depressive Symptoms and Sleep Quality in Self-Reported Insomniac, PMID: 34444980, PMCID: PMC8402034, DOI: 10.3390/nu13082820, DOI - PMC - PubMed.
8. Eloise J Kuijer, Laura Steenbergen, The microbiota-gut-brain axis in hippocampus-dependent learning and memory, PMID: 37380040, DOI: 10.1016/j.neubiorev.2023.105296, DOI - PMC - PubMed.
9. Laura Steenbergen, Roberta Sellaro, Saskia van Hemert, Jos A Bosch, Lorenza S Colzato, A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood, PMID: 25862297, DOI: 10.1016/j.bbi.2015.04.003, DOI - PMC – PubMed.
10. Tracey L K Bear, Julie E Dalziel, Jane Coad, Nicole C Roy, Christine A Butts, Pramod K Gopal, The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety, PMID: 32149335 PMCID: PMC7360462 DOI: 10.1093/advances/nmaa016, DOI - PMC - PubMed.
11. Gabriela Ribeiro, Aimone Ferri, Gerard Clarke, and John Cryan, Diet and the microbiota–gut–brain-axis: a primer for clinical nutrition, PMID: 36102353, PMCID: PMC9553262, DOI: 10.1097/MCO.0000000000000874, DOI - PMC - PubMed.

12. Kazunori Suda and Kazunori Matsuda, Gerard M. Moloney, Underlying Mechanisms via the Gut-Brain Axis and the Modulating Role of Probiotics, doi: 10.3390/ijms23031172 DOI - PMC - PubMed.
13. Lijia Chang, Yan Wei, Kenji Hashimoto, Brain-gut-microbiota axis in depression: A historical overview and future directions, PMID: 35151796, DOI: 10.1016/j.brainresbull.2022.02.004, DOI - PMC – PubMed.
14. Suda, K.; Matsuda, K. How Microbes Affect Depression: Underlying Mechanisms via the Gut–Brain Axis and the Modulating Role of Probiotics. Int. J. Mol. Sci, 2022; 23: 1172. https://doi.org/10.3390/ijms23031172.
15. Amy Wallis 1, Michelle Ball 2, Henry Butt 3, Donald P Lewis 4, Sandra McKechnie 5, Phillip Paull 3, Amber Jaa-Kwee 5, Dorothy Bruck 2, Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome PMCID: PMC5801817, DOI: 10.1186/s12967-018-1392-z, DOI - PMC - PubMed.